ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2516

Exome-Wide Rare Variant Association Study of Takayasu’s Arteritis

Yiming Luo1, Zuoming deng2, Kaitlin Quinn3, Keith Sikora4, Daniel Kastner5, Krzysztof Kiryluk1, Amr Sawalha6, Peter Merkel7 and Peter Grayson8, and the Vasculitis Clinical Research Consortium, 1Columbia University Irving Medical Center, New York, NY, 2National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 4National Institutes of Health, Bethesda, MD, 5National Human Genome Research Institute, Bethesda, MD, Bethesda, MD, 6University of Pittsburgh, Pittsburgh, 7University of Pennsylvania, Philadelphia, PA, 8National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD

Meeting: ACR Convergence 2024

Keywords: genetics, genomics, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Takayasu’s arteritis (TAK) is a rare inflammatory disease primarily involving the aorta and its major branches. Multiple genetic association studies on common variants in TAK have led to progress in understanding the mechanisms of TAK. However, the contribution of rare variants to TAK is still poorly understood.

Methods: This is a case-control exome-wide rare variant association study (RVAS) in a multi-ancestral population. Exome controls were selected from among individuals who did not have a known autoimmune phenotype. Multiple quality control steps were implemented to select high-quality exonic variants with balanced coverage between cases and controls. Principal component analysis (PCA) and kinship pruning were performed to include only unrelated individuals. PCA-based clustering analysis was performed to generate ancestry clusters. Nine collapsing models were defined based on population allele frequency and predicted deleterious effects (Table 1). Gene-level collapsing analysis was performed using Cochran-Mantel-Haenszel test stratified by the ancestry cluster membership.

Results: After quality control, the study included data from 206 patients with TAK and 11,957 controls. Participants were clustered into seven group based on their ancestral background (“European 1”, “European 2”, “African and Latinx”, “Latinx”, “East Asian”, “South Asian”, and “Middle Eastern”). No gene reached exome-wide statistical significance in any of the collapsing models. In the Flexible Model, IL15 was top-ranked (2.5% vs 0.2%, odds ratio (OR) = 14, p = 8.3 x 10-5). In the Rare Protein-Truncating Variant (PTV) Model, there was a numerically higher burden of PTVs in NFKB1 (1.0% vs 0.009%, OR = 91, p = 0.002). Two patients with TAK had a frameshift (P444fs) and stop-gained (W295X) variant in NFKB1, respectively. These two NFKB1 variants are pathogenic for haploinsufficiency of the Nuclear Factor Kappa B Subunit 1 (NF-kappaB1) p50 subunit based on the American College of Medical Genetics and Genomics guideline.

Conclusion: Our RVAS did not find statistically significant genes associated with TAK, but was limited by a small sample size of the case cohort. A numerically higher burden of rare variants in IL15, a pro-inflammatory cytokine that regulates the activation of T and Natural Killer cells, were observed in TAK. We have also found two individuals with TAK who had a genetic diagnosis of haploinsufficiency of the NF-kappaB1 p50 subunit, whose phenotypes have been reported to involve a broad spectrum of immunodeficiency, autoimmunity, autoinflammation, and cancer. Our study supports TAK as likely being an inflammatory manifestation of the NFKB1-related monogenic phenotypes.

Supporting image 1

Table 1


Disclosures: Y. Luo: None; Z. deng: None; K. Quinn: None; K. Sikora: Amgen, 3; D. Kastner: None; K. Kiryluk: None; A. Sawalha: None; P. Merkel: AbbVie/Abbott, 2, 5, Amgen, 2, 5, argenx, 2, AstraZeneca, 2, 5, Boehringer Ingelheim, 3, 5, Bristol Myers Squibb, 2, 5, Cabaletta, 2, ChemoCentryx, 2, 5, CSL Behring, 2, Dynacure, 2, Eicos, 5, Electra, 5, EMDSerano, 2, Forbius, 2, 5, Genentech/Roche, 2, 5, Genzyme/Sanofi, 2, 5, GSK, 2, 5, HiBio, 2, Immagene, 2, InflaRx, 2, 5, Jannsen, 2, Kiniksa, 2, Kyverna, 2, Magenta, 2, MiroBio, 2, Neutrolis, 2, Novartis, 2, NS Pharma, 2, Pfizer, 2, Q32, 2, 11, Regeneron, 2, Sanofi, 5, Sparrow, 2, 11, Takeda, 2, 5, Talaris, 2, UpToDate, 9, Visterra, 2; P. Grayson: None.

To cite this abstract in AMA style:

Luo Y, deng Z, Quinn K, Sikora K, Kastner D, Kiryluk K, Sawalha A, Merkel P, Grayson P. Exome-Wide Rare Variant Association Study of Takayasu’s Arteritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/exome-wide-rare-variant-association-study-of-takayasus-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exome-wide-rare-variant-association-study-of-takayasus-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology